Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU

Completed

• Conditions: COVID-19 Disease
• Interventions: Other: File inquiry

• Registration Number: NCT04757792
• Lead Sponsor: Benha University

Brief Summary

Retrospective multicenter study to evaluate the data of COVID-19 patients who were admitted to university hospitals in relation to their recent administration or maintenance on non-steroidal anti-inflammatory drugs (NSAID) prior to have COVID-19 disease and to analyze it in relation to outcome of these patients.

Detailed Description

The data contained in hospital registry were collected, categorized into demographic, previous medical history, the use of NSAID as maintenance therapy or its recent administration before diagnosis of COVID-19 disease, presenting manifestations, laboratory and CT findings, applied therapies or interventions. Outcomes will be categorized as survival and non-survival outcome. Survivors will be subdivided as complete recovery or recovery with getting new morbidities. Mortality was subdivided as total hospital and ICU mortality. Data will be statistically analyzed in relation to outcomes

Study Timeline

• Study Start: 2020-06-06
• Status Verified: 2021-02
• Primary Completion: 2021-02-01
• Study Completion: 2021-02-11
• Study First Submitted: 2021-02-11
• Study First Submitted QC: 2021-02-16
• Last Update Submitted: 2021-02-16
• Study First Posted: 2021-02-17
• Last Update Posted: 2021-02-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 475

Inclusion Criteria

• assured diagnosis of COVID-19 by RT-PCR

Exclusion Criteria

• No

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
No NSAID	File inquiry	included patients who did not receive NSAID prior to having COVID-19 disease
Apsirin	File inquiry	included patients who received acetylsalicylic acid (ASA) prior to having COVID-19 disease
Celecoxib	File inquiry	included patients who received celecoxib (CEL) prior to having COVID-19 disease
Miscellaneous	File inquiry	included patients who received miscellaneous NSAID other than ASA or CEL prior to having COVID-19 disease

Primary Outcome Measures

Name	Time	Method
Mortality rate	6 months	number of patients who were died secondary to COVID-19 disease or its complications

Trial Locations

Locations (1)

Faculty of Medicine; 🇪🇬 Banhā, Qalubia, Egypt